Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Clostridium difficile is a significant nosocomial and community-acquired pathogen, and is the leading cause of antibiotic-induced diarrhea associated with high morbidity and mortality. Given that the treatment outcome depends on the severity of C. difficile infection (CDI), we aimed to establish an efficient method of assessing severity, and focused on the stool biomarker fecal calprotectin (FC). FC directly reflects the intestinal inflammation status of a patient, and can aid in interpreting the current guidelines, which requires the integration of indirect laboratory parameters. The distinction of 80 patients with CDI versus 71 healthy controls and 30 severe infection cases versus 50 mild cases was possible using FC as a marker. The area under the receiver operating characteristic curves were 0.821 and 0.746 with a sensitivity of 75% and 70% and specificity of 79% and 80%, for severe versus mild cases, respectively. We suggest FC as a predictive marker for assessing CDI severity, which is expected to improve the clinical management of CDI.
Abstract
Clostridium difficile is a significant nosocomial and community-acquired pathogen, and is the leading cause of antibiotic-induced diarrhea associated with high morbidity and mortality. Given that the treatment outcome depends on the severity of C. difficile infection (CDI), we aimed to establish an efficient method of assessing severity, and focused on the stool biomarker fecal calprotectin (FC). FC directly reflects the intestinal inflammation status of a patient, and can aid in interpreting the current guidelines, which requires the integration of indirect laboratory parameters. The distinction of 80 patients with CDI versus 71 healthy controls and 30 severe infection cases versus 50 mild cases was possible using FC as a marker. The area under the receiver operating characteristic curves were 0.821 and 0.746 with a sensitivity of 75% and 70% and specificity of 79% and 80%, for severe versus mild cases, respectively. We suggest FC as a predictive marker for assessing CDI severity, which is expected to improve the clinical management of CDI.
참고문헌 (20)
- 김영아, "공중보건에 부담이 되는 Clostridium difficile 지역사회 감염의 증가", Annals of Clinical Microbiology, 19(1), pp.7~12 (2016), 대한임상미생물학회
- Poutanen SM, "Clostridium difficile-associated diarrhea in adults", CMAJ, 171, pp.51~58 (2004)
- Cohen SH, "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)", Infect Control Hosp Epidemiol, 31, pp.431~455 (2010)
- Debast SB, "European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection", Clin Microbiol Infect, 20(S2), pp.S1~S26 (2014)
- Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
- Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
- Aradhyula S, "Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function", South Med J, 99, pp.518~520 (2006)
- 김희정, "Evaluation of a Rapid Membrane Enzyme Immunoassay for the Simultaneous Detection of Glutamate Dehydrogenase and Toxin for the Diagnosis of Clostridium difficile Infection", Annals of Laboratory Medicine, 34(3), pp.235~239 (2014), 대한진단검사의학회
- Boone JH, "Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection", Eur J Clin Microbiol Infect Dis, 32, pp.1517~1523 (2013)
- El Feghaly RE, "Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection", Clin Infect Dis, 56, pp.1713~1721 (2013)
- Shastri YM, "Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea", Am J Med, 121, pp.1099~1106 (2008)
- 이강문, "Fecal Biomarkers in Inflammatory Bowel Disease", Intestinal research, 11(2), pp.73~78 (2013), 대한장연구학회
- Steinbakk M, "Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin", Lancet, 336, pp.763~765 (1990)
- Caccaro R, "Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease", Expert Rev Clin Immunol, 6, pp.551~558 (2010)
- Whitehead SJ, "Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples?", J Med Microbiol, 63, pp.590~593 (2014)
- van Rheenen PF, "Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis", BMJ, 341, pp.c3369~ (2010)
- Leekha S, "General principles of antimicrobial therapy", Mayo Clin Proc, 86, pp.156~167 (2011)
- Crobach MJ, "European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI)", Clin Microbiol Infect, 15, pp.1053~1066 (2009)
- Waugh N, "Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation", Health Technol Assess, 17, pp.1~211 (2013)
- Swale A, "Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study", PLoS One, 9, pp.e106118~ (2014)